2. Academic Validation
  3. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates

  • Sci Rep. 2019 Feb 21;9(1):2443. doi: 10.1038/s41598-019-38745-x.
Maria José Costa 1,  Jyothirmayee Kudaravalli 2,  Jing-Tyan Ma 2,  Wei-Hsien Ho 2 3,  Kathy Delaria 2 4,  Charles Holz 2 4,  Angela Stauffer 5,  Allison Given Chunyk 5,  Qing Zong 6,  Eileen Blasi 6,  Bernard Buetow 6,  Thomas-Toan Tran 2 7,  Kevin Lindquist 2,  Magdalena Dorywalska 2,  Arvind Rajpal 2 8,  David L Shelton 2,  Pavel Strop 2 8,  Shu-Hui Liu 2 9
Affiliations

Affiliations

  • 1 Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA. mariajstcosta@gmail.com.
  • 2 Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.
  • 3 Alector, 151, Oyster Point Blvd, suite 300, South San Francisco, CA, 94080, USA.
  • 4 Grifols Diagnostic Solutions, 6455 Christie Ave B-334C, Emeryville, CA, 94608, USA.
  • 5 BioMedicine Design, Medicinal Sciences, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA.
  • 6 Drug Safety Research and Development, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA.
  • 7 NGM Biopharmaceuticals, Inc, 630 Gateway Blvd, South San Francisco, CA, 94080, USA.
  • 8 Bristol-Myers Squibb, 700 Bay Rd suite A, Redwood City, CA, 94063, USA.
  • 9 Multitude Therapeutics, Abmart, Redwood City, CA, 94063, USA.
PMID: 30792442 DOI: 10.1038/s41598-019-38745-x
Abstract

Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers. Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens. The C-X-C motif Chemokine Receptor 4 (CXCR4) is attractive for targeted therapy of haematological cancers, given its expression in multiple tumour types and role in Cancer "homing" to bone marrow. However, CXCR4 is also expressed in haematopoietic cells and Other normal tissues, raising safety challenges to the development of anti-CXCR4 ADCs for Cancer treatment. Here, we designed the first anti-CXCR4 ADC with favourable therapeutic index, effective in xenografts of haematopoietic cancers resistant to standard of care and anti-CXCR4 Antibodies. We screened multiple ADC configurations, by varying type of linker-payload, drug-to-antibody ratio (DAR), affinity and Fc format. The optimal ADC bears a Non-cleavable Linker, Auristatin as payload at DAR = 4 and a low affinity antibody with effector-reduced Fc. Contrary to Other drugs targeting CXCR4, anti-CXCR4 ADCs effectively eliminated Cancer cells as monotherapy, while minimizing leucocytosis. The optimal ADC selectively eliminated CXCR4+ Cancer cells in solid tumours, but showed limited toxicity to normal CXCR4+ tissues, sparing haematopoietic stem cells and progenitors. Our work provides proof-of-concept that through empirical ADC design, it is possible to target proteins with broad normal tissue expression.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z